| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 100 | 2024 | 965 | 22.870 |
Why?
|
| Brain Ischemia | 52 | 2024 | 398 | 13.840 |
Why?
|
| Endovascular Procedures | 22 | 2024 | 218 | 6.680 |
Why?
|
| Thrombectomy | 43 | 2024 | 158 | 6.180 |
Why?
|
| Intracranial Embolism | 8 | 2022 | 29 | 5.750 |
Why?
|
| Plaque, Atherosclerotic | 8 | 2023 | 54 | 5.690 |
Why?
|
| Atrial Fibrillation | 12 | 2024 | 288 | 5.110 |
Why?
|
| Neurology | 7 | 2023 | 70 | 3.390 |
Why?
|
| Carotid Artery Diseases | 6 | 2022 | 97 | 3.260 |
Why?
|
| Perfusion Imaging | 6 | 2023 | 50 | 3.170 |
Why?
|
| Arterial Occlusive Diseases | 6 | 2023 | 107 | 2.490 |
Why?
|
| Retrospective Studies | 64 | 2024 | 8496 | 2.380 |
Why?
|
| Humans | 148 | 2024 | 86678 | 2.370 |
Why?
|
| Cerebral Infarction | 11 | 2023 | 71 | 2.360 |
Why?
|
| Thrombolytic Therapy | 17 | 2024 | 220 | 2.180 |
Why?
|
| Pandemics | 12 | 2024 | 740 | 2.100 |
Why?
|
| Thrombosis | 5 | 2022 | 296 | 2.030 |
Why?
|
| Aged | 65 | 2024 | 18423 | 1.950 |
Why?
|
| Treatment Outcome | 51 | 2024 | 7998 | 1.920 |
Why?
|
| Carotid Stenosis | 3 | 2023 | 112 | 1.840 |
Why?
|
| Subarachnoid Hemorrhage | 4 | 2021 | 137 | 1.820 |
Why?
|
| Fibrinolytic Agents | 10 | 2024 | 202 | 1.720 |
Why?
|
| Foramen Ovale, Patent | 2 | 2022 | 18 | 1.690 |
Why?
|
| Cerebral Veins | 2 | 2022 | 30 | 1.670 |
Why?
|
| Tomography, X-Ray Computed | 12 | 2024 | 2601 | 1.610 |
Why?
|
| Cerebrovascular Disorders | 2 | 2024 | 143 | 1.600 |
Why?
|
| Tissue Plasminogen Activator | 9 | 2023 | 162 | 1.580 |
Why?
|
| Brain Injuries | 2 | 2023 | 161 | 1.560 |
Why?
|
| Time-to-Treatment | 5 | 2022 | 98 | 1.520 |
Why?
|
| Disability Evaluation | 10 | 2022 | 136 | 1.480 |
Why?
|
| Aged, 80 and over | 37 | 2024 | 6513 | 1.460 |
Why?
|
| Nervous System Diseases | 5 | 2021 | 151 | 1.440 |
Why?
|
| Venous Thrombosis | 5 | 2024 | 243 | 1.430 |
Why?
|
| Nervous System | 4 | 2013 | 86 | 1.410 |
Why?
|
| Risk Factors | 29 | 2023 | 5420 | 1.400 |
Why?
|
| Stroke Rehabilitation | 3 | 2021 | 41 | 1.370 |
Why?
|
| Intracranial Hemorrhages | 15 | 2024 | 120 | 1.360 |
Why?
|
| Carotid Arteries | 5 | 2023 | 127 | 1.290 |
Why?
|
| Dementia | 2 | 2023 | 187 | 1.250 |
Why?
|
| Computed Tomography Angiography | 6 | 2023 | 131 | 1.220 |
Why?
|
| Middle Aged | 51 | 2022 | 25040 | 1.190 |
Why?
|
| Female | 65 | 2024 | 44550 | 1.190 |
Why?
|
| Cerebral Hemorrhage | 7 | 2022 | 325 | 1.160 |
Why?
|
| Male | 62 | 2024 | 40988 | 1.140 |
Why?
|
| Meningoencephalitis | 2 | 2023 | 10 | 1.110 |
Why?
|
| Editorial Policies | 2 | 2023 | 32 | 1.100 |
Why?
|
| Registries | 13 | 2021 | 703 | 1.060 |
Why?
|
| Neuroimaging | 5 | 2023 | 113 | 1.050 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 316 | 1.040 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 301 | 1.040 |
Why?
|
| Reperfusion | 2 | 2024 | 31 | 1.010 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 2 | 2021 | 12 | 1.000 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2023 | 2 | 0.950 |
Why?
|
| Myositis, Inclusion Body | 1 | 2023 | 2 | 0.950 |
Why?
|
| Cohort Studies | 13 | 2023 | 2768 | 0.920 |
Why?
|
| Status Epilepticus | 1 | 2023 | 31 | 0.920 |
Why?
|
| Embolism | 2 | 2022 | 31 | 0.900 |
Why?
|
| Muscular Dystrophies, Limb-Girdle | 1 | 2023 | 14 | 0.900 |
Why?
|
| Intracranial Thrombosis | 4 | 2024 | 27 | 0.890 |
Why?
|
| Brain Death | 1 | 2023 | 69 | 0.890 |
Why?
|
| Independent Living | 1 | 2023 | 18 | 0.890 |
Why?
|
| Gray Matter | 1 | 2023 | 33 | 0.880 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2021 | 584 | 0.880 |
Why?
|
| Hypoxia, Brain | 1 | 2023 | 41 | 0.880 |
Why?
|
| Virus Diseases | 1 | 2023 | 97 | 0.880 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2024 | 103 | 0.880 |
Why?
|
| Carotid Artery, Internal | 2 | 2020 | 69 | 0.860 |
Why?
|
| Patient Discharge | 4 | 2021 | 300 | 0.850 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2022 | 49 | 0.850 |
Why?
|
| Platelet Aggregation Inhibitors | 6 | 2024 | 134 | 0.840 |
Why?
|
| Disease Progression | 7 | 2017 | 1532 | 0.840 |
Why?
|
| Glucocorticoids | 1 | 2024 | 352 | 0.810 |
Why?
|
| Miller Fisher Syndrome | 1 | 2020 | 1 | 0.770 |
Why?
|
| Cranial Nerve Diseases | 1 | 2020 | 7 | 0.770 |
Why?
|
| Neuritis | 1 | 2020 | 8 | 0.770 |
Why?
|
| Ophthalmoplegia | 1 | 2020 | 11 | 0.760 |
Why?
|
| Hospital Mortality | 7 | 2021 | 350 | 0.760 |
Why?
|
| Betacoronavirus | 2 | 2020 | 258 | 0.750 |
Why?
|
| Anticoagulants | 5 | 2024 | 408 | 0.740 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 183 | 0.730 |
Why?
|
| Patient Transfer | 1 | 2021 | 91 | 0.730 |
Why?
|
| Vaccines | 1 | 2021 | 80 | 0.730 |
Why?
|
| Severity of Illness Index | 7 | 2018 | 1802 | 0.720 |
Why?
|
| Time Factors | 14 | 2022 | 5214 | 0.720 |
Why?
|
| Intracranial Aneurysm | 2 | 2021 | 158 | 0.720 |
Why?
|
| Hyoid Bone | 1 | 2019 | 12 | 0.700 |
Why?
|
| Perceptual Disorders | 1 | 2019 | 12 | 0.700 |
Why?
|
| Interdisciplinary Communication | 2 | 2017 | 130 | 0.700 |
Why?
|
| Paresis | 1 | 2019 | 15 | 0.700 |
Why?
|
| Hair | 1 | 2019 | 56 | 0.680 |
Why?
|
| Adult | 27 | 2023 | 25659 | 0.680 |
Why?
|
| Heart Defects, Congenital | 1 | 2022 | 351 | 0.680 |
Why?
|
| Brain | 6 | 2023 | 2216 | 0.660 |
Why?
|
| Spasm | 1 | 2018 | 16 | 0.650 |
Why?
|
| Cerebrovascular Circulation | 1 | 2019 | 212 | 0.620 |
Why?
|
| Prospective Studies | 9 | 2023 | 4214 | 0.620 |
Why?
|
| Efficiency, Organizational | 1 | 2017 | 58 | 0.610 |
Why?
|
| Erythrocyte Indices | 1 | 2017 | 10 | 0.600 |
Why?
|
| Vertebral Artery Dissection | 1 | 2016 | 11 | 0.590 |
Why?
|
| Motion Pictures | 1 | 2016 | 11 | 0.580 |
Why?
|
| Medical Staff, Hospital | 1 | 2017 | 107 | 0.580 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 426 | 0.570 |
Why?
|
| Prevalence | 4 | 2022 | 1239 | 0.560 |
Why?
|
| Demyelinating Diseases | 1 | 2016 | 68 | 0.560 |
Why?
|
| Aspergillosis | 1 | 2016 | 41 | 0.560 |
Why?
|
| Medulla Oblongata | 1 | 2016 | 89 | 0.550 |
Why?
|
| Hospitalization | 7 | 2021 | 851 | 0.550 |
Why?
|
| Malnutrition | 1 | 2016 | 34 | 0.550 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2016 | 78 | 0.550 |
Why?
|
| Functional Laterality | 1 | 2016 | 201 | 0.540 |
Why?
|
| Brain Concussion | 1 | 2016 | 59 | 0.540 |
Why?
|
| Time Management | 1 | 2015 | 9 | 0.530 |
Why?
|
| Factor VIII | 1 | 2015 | 7 | 0.520 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2015 | 40 | 0.510 |
Why?
|
| Brain Infarction | 1 | 2015 | 22 | 0.510 |
Why?
|
| Basilar Artery | 3 | 2023 | 41 | 0.510 |
Why?
|
| Risk Assessment | 7 | 2023 | 2264 | 0.500 |
Why?
|
| Blood Pressure | 4 | 2020 | 1144 | 0.490 |
Why?
|
| Rehabilitation Centers | 1 | 2013 | 8 | 0.480 |
Why?
|
| Patient Care | 1 | 2015 | 100 | 0.470 |
Why?
|
| Chronic Pain | 1 | 2016 | 145 | 0.470 |
Why?
|
| Age Factors | 4 | 2020 | 1852 | 0.470 |
Why?
|
| Magnesium | 1 | 2013 | 177 | 0.440 |
Why?
|
| Inpatients | 4 | 2024 | 298 | 0.440 |
Why?
|
| Infarction | 2 | 2022 | 26 | 0.440 |
Why?
|
| Internship and Residency | 3 | 2017 | 1010 | 0.430 |
Why?
|
| Japan | 2 | 2023 | 307 | 0.430 |
Why?
|
| Glucose | 1 | 2015 | 638 | 0.420 |
Why?
|
| Predictive Value of Tests | 7 | 2021 | 1673 | 0.420 |
Why?
|
| Analgesics, Opioid | 1 | 2016 | 413 | 0.410 |
Why?
|
| Logistic Models | 8 | 2016 | 1188 | 0.400 |
Why?
|
| United States | 12 | 2024 | 6681 | 0.390 |
Why?
|
| Eligibility Determination | 2 | 2022 | 32 | 0.390 |
Why?
|
| Aspirin | 2 | 2024 | 156 | 0.380 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2023 | 3362 | 0.380 |
Why?
|
| Decision Making | 1 | 2016 | 642 | 0.370 |
Why?
|
| Cross-Sectional Studies | 8 | 2023 | 1621 | 0.370 |
Why?
|
| Sinus Thrombosis, Intracranial | 2 | 2021 | 13 | 0.350 |
Why?
|
| Sleep | 2 | 2024 | 444 | 0.340 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 2021 | 122 | 0.340 |
Why?
|
| Echocardiography, Transesophageal | 3 | 2021 | 344 | 0.330 |
Why?
|
| Recovery of Function | 5 | 2021 | 272 | 0.330 |
Why?
|
| Biomarkers | 4 | 2024 | 1718 | 0.320 |
Why?
|
| Coronary Artery Disease | 1 | 2012 | 350 | 0.320 |
Why?
|
| Odds Ratio | 6 | 2016 | 680 | 0.300 |
Why?
|
| Chi-Square Distribution | 5 | 2016 | 364 | 0.300 |
Why?
|
| Prognosis | 8 | 2020 | 3680 | 0.300 |
Why?
|
| Mechanical Thrombolysis | 2 | 2023 | 15 | 0.290 |
Why?
|
| Surveys and Questionnaires | 4 | 2022 | 2504 | 0.280 |
Why?
|
| Electroencephalography | 2 | 2023 | 709 | 0.270 |
Why?
|
| Emergency Service, Hospital | 3 | 2016 | 484 | 0.260 |
Why?
|
| Patient Selection | 2 | 2019 | 686 | 0.260 |
Why?
|
| Fatal Outcome | 2 | 2016 | 295 | 0.260 |
Why?
|
| Administration, Oral | 2 | 2023 | 684 | 0.260 |
Why?
|
| Constriction, Pathologic | 2 | 2023 | 213 | 0.250 |
Why?
|
| Neurologic Examination | 3 | 2013 | 118 | 0.250 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2023 | 865 | 0.250 |
Why?
|
| Alberta | 2 | 2024 | 8 | 0.240 |
Why?
|
| Cross Infection | 3 | 2015 | 141 | 0.240 |
Why?
|
| Carotid Artery, Internal, Dissection | 1 | 2024 | 18 | 0.240 |
Why?
|
| Leukocytosis | 2 | 2014 | 16 | 0.230 |
Why?
|
| Sex Factors | 3 | 2023 | 1055 | 0.230 |
Why?
|
| Neuromyelitis Optica | 1 | 2023 | 22 | 0.230 |
Why?
|
| Seizures | 2 | 2023 | 297 | 0.230 |
Why?
|
| Blood Coagulation | 1 | 2023 | 91 | 0.230 |
Why?
|
| Young Adult | 9 | 2020 | 5980 | 0.230 |
Why?
|
| Arousal | 1 | 2023 | 170 | 0.220 |
Why?
|
| Cysts | 1 | 2023 | 104 | 0.220 |
Why?
|
| Patients | 1 | 2023 | 100 | 0.220 |
Why?
|
| Educational Status | 1 | 2023 | 190 | 0.220 |
Why?
|
| Perfusion | 1 | 2023 | 203 | 0.220 |
Why?
|
| Length of Stay | 3 | 2020 | 704 | 0.220 |
Why?
|
| Anticonvulsants | 1 | 2023 | 126 | 0.210 |
Why?
|
| Dabigatran | 1 | 2022 | 24 | 0.210 |
Why?
|
| Forecasting | 1 | 2023 | 305 | 0.210 |
Why?
|
| Hematoma | 2 | 2023 | 104 | 0.210 |
Why?
|
| Cognition | 2 | 2023 | 571 | 0.200 |
Why?
|
| New Jersey | 1 | 2021 | 4 | 0.200 |
Why?
|
| Drug Therapy, Combination | 1 | 2024 | 895 | 0.200 |
Why?
|
| Headache | 2 | 2023 | 73 | 0.200 |
Why?
|
| Incidence | 2 | 2023 | 1578 | 0.200 |
Why?
|
| Clinical Decision-Making | 1 | 2023 | 257 | 0.200 |
Why?
|
| Hypokinesia | 1 | 2021 | 3 | 0.200 |
Why?
|
| Autoimmune Diseases | 1 | 2023 | 241 | 0.200 |
Why?
|
| Warfarin | 1 | 2022 | 103 | 0.200 |
Why?
|
| Hospitals | 1 | 2023 | 294 | 0.190 |
Why?
|
| Administration, Intravenous | 2 | 2020 | 50 | 0.190 |
Why?
|
| Neuropsychological Tests | 1 | 2023 | 502 | 0.190 |
Why?
|
| Tobacco Use | 1 | 2020 | 24 | 0.190 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 94 | 0.190 |
Why?
|
| Benchmarking | 1 | 2021 | 79 | 0.190 |
Why?
|
| Feeding Behavior | 1 | 2023 | 324 | 0.190 |
Why?
|
| Terminology as Topic | 2 | 2012 | 217 | 0.180 |
Why?
|
| Hypotension | 1 | 2020 | 70 | 0.180 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 153 | 0.180 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2020 | 35 | 0.180 |
Why?
|
| Arterial Pressure | 1 | 2020 | 38 | 0.180 |
Why?
|
| Preoperative Period | 1 | 2020 | 91 | 0.180 |
Why?
|
| Automation | 1 | 2020 | 106 | 0.180 |
Why?
|
| Rivaroxaban | 1 | 2019 | 12 | 0.180 |
Why?
|
| Global Health | 1 | 2021 | 193 | 0.180 |
Why?
|
| Child | 2 | 2023 | 6928 | 0.170 |
Why?
|
| Cerebral Cortex | 1 | 2023 | 584 | 0.170 |
Why?
|
| Secondary Prevention | 1 | 2019 | 162 | 0.160 |
Why?
|
| Blood Glucose | 2 | 2012 | 873 | 0.160 |
Why?
|
| Physical Examination | 1 | 2019 | 149 | 0.160 |
Why?
|
| Aging | 1 | 2023 | 691 | 0.160 |
Why?
|
| Recurrence | 2 | 2019 | 1139 | 0.160 |
Why?
|
| Physician-Nurse Relations | 1 | 2017 | 2 | 0.160 |
Why?
|
| Upper Extremity | 1 | 2018 | 52 | 0.150 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2017 | 13 | 0.150 |
Why?
|
| Brain Stem Infarctions | 1 | 2017 | 5 | 0.150 |
Why?
|
| Nursing Staff, Hospital | 1 | 2017 | 42 | 0.150 |
Why?
|
| Artifacts | 1 | 2019 | 244 | 0.150 |
Why?
|
| Pancytopenia | 1 | 2017 | 23 | 0.150 |
Why?
|
| Cerebral Intraventricular Hemorrhage | 1 | 2016 | 9 | 0.150 |
Why?
|
| ROC Curve | 3 | 2016 | 752 | 0.150 |
Why?
|
| Societies, Medical | 1 | 2020 | 573 | 0.150 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 1001 | 0.150 |
Why?
|
| Decompressive Craniectomy | 1 | 2016 | 18 | 0.140 |
Why?
|
| Computer Security | 1 | 2016 | 16 | 0.140 |
Why?
|
| Osmotic Pressure | 1 | 2016 | 21 | 0.140 |
Why?
|
| Inventions | 1 | 2016 | 13 | 0.140 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2016 | 92 | 0.140 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 66 | 0.140 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2017 | 85 | 0.140 |
Why?
|
| Smartphone | 1 | 2016 | 36 | 0.140 |
Why?
|
| Stents | 3 | 2024 | 377 | 0.140 |
Why?
|
| White Matter | 1 | 2017 | 80 | 0.140 |
Why?
|
| Cardiomegaly | 1 | 2016 | 111 | 0.140 |
Why?
|
| Phenotype | 1 | 2022 | 2380 | 0.140 |
Why?
|
| Wakefulness | 1 | 2016 | 134 | 0.140 |
Why?
|
| History, 21st Century | 1 | 2016 | 175 | 0.140 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1019 | 0.140 |
Why?
|
| Viral Load | 1 | 2016 | 150 | 0.140 |
Why?
|
| Outpatients | 1 | 2016 | 94 | 0.130 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2015 | 5 | 0.130 |
Why?
|
| Pneumonia | 2 | 2021 | 179 | 0.130 |
Why?
|
| Area Under Curve | 2 | 2015 | 334 | 0.130 |
Why?
|
| History, 20th Century | 1 | 2016 | 312 | 0.130 |
Why?
|
| Heart Atria | 1 | 2016 | 250 | 0.130 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2017 | 294 | 0.130 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 1566 | 0.120 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2016 | 262 | 0.120 |
Why?
|
| Follow-Up Studies | 4 | 2022 | 3642 | 0.120 |
Why?
|
| Medical Errors | 1 | 2015 | 115 | 0.120 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2020 | 1204 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 1169 | 0.120 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2013 | 31 | 0.120 |
Why?
|
| Quality Improvement | 1 | 2017 | 429 | 0.120 |
Why?
|
| Opioid-Related Disorders | 1 | 2016 | 161 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 160 | 0.110 |
Why?
|
| Ticlopidine | 1 | 2013 | 25 | 0.110 |
Why?
|
| Community-Acquired Infections | 1 | 2013 | 63 | 0.110 |
Why?
|
| Patient Admission | 1 | 2013 | 112 | 0.110 |
Why?
|
| Acute Disease | 1 | 2015 | 826 | 0.110 |
Why?
|
| Deglutition Disorders | 1 | 2013 | 115 | 0.100 |
Why?
|
| Down-Regulation | 1 | 2013 | 506 | 0.100 |
Why?
|
| Iran | 2 | 2021 | 15 | 0.100 |
Why?
|
| Echocardiography | 1 | 2016 | 911 | 0.100 |
Why?
|
| Sex Characteristics | 2 | 2024 | 319 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 636 | 0.100 |
Why?
|
| Adolescent | 3 | 2023 | 8984 | 0.100 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2011 | 93 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2020 | 2207 | 0.090 |
Why?
|
| Continuity of Patient Care | 1 | 2011 | 169 | 0.090 |
Why?
|
| Blood Pressure Determination | 2 | 2020 | 90 | 0.090 |
Why?
|
| Infusions, Intravenous | 2 | 2021 | 430 | 0.080 |
Why?
|
| Sex Distribution | 2 | 2021 | 173 | 0.080 |
Why?
|
| Comorbidity | 2 | 2021 | 944 | 0.060 |
Why?
|
| Middle Cerebral Artery | 1 | 2024 | 21 | 0.060 |
Why?
|
| Aquaporin 4 | 1 | 2023 | 8 | 0.060 |
Why?
|
| Delayed Diagnosis | 1 | 2023 | 29 | 0.060 |
Why?
|
| Posterior Cerebral Artery | 1 | 2023 | 2 | 0.060 |
Why?
|
| Rare Diseases | 1 | 2023 | 59 | 0.060 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 48 | 0.060 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2022 | 10 | 0.060 |
Why?
|
| Arteries | 1 | 2024 | 177 | 0.060 |
Why?
|
| Intention to Treat Analysis | 1 | 2022 | 72 | 0.060 |
Why?
|
| Punctures | 1 | 2022 | 29 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2023 | 234 | 0.050 |
Why?
|
| Angioplasty | 1 | 2022 | 70 | 0.050 |
Why?
|
| Workflow | 1 | 2022 | 77 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2024 | 268 | 0.050 |
Why?
|
| Anesthesia, General | 1 | 2022 | 114 | 0.050 |
Why?
|
| Egypt | 1 | 2021 | 13 | 0.050 |
Why?
|
| Cranial Sinuses | 1 | 2021 | 15 | 0.050 |
Why?
|
| Hospitals, Low-Volume | 1 | 2021 | 18 | 0.050 |
Why?
|
| Consciousness Disorders | 1 | 2021 | 9 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2023 | 455 | 0.050 |
Why?
|
| Spain | 1 | 2021 | 33 | 0.050 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 28 | 0.050 |
Why?
|
| Hospitals, High-Volume | 1 | 2021 | 35 | 0.050 |
Why?
|
| Europe | 1 | 2021 | 309 | 0.050 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2020 | 8 | 0.050 |
Why?
|
| Vision Disorders | 1 | 2021 | 75 | 0.050 |
Why?
|
| Stroke Volume | 1 | 2022 | 456 | 0.050 |
Why?
|
| Latin America | 1 | 2019 | 14 | 0.050 |
Why?
|
| Vascular Diseases | 1 | 2020 | 121 | 0.040 |
Why?
|
| Factor Xa Inhibitors | 1 | 2019 | 22 | 0.040 |
Why?
|
| Mobility Limitation | 1 | 2019 | 19 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 62 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2020 | 361 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2023 | 1807 | 0.040 |
Why?
|
| Critical Illness | 1 | 2021 | 294 | 0.040 |
Why?
|
| Critical Care | 1 | 2021 | 370 | 0.040 |
Why?
|
| Late Onset Disorders | 1 | 2017 | 3 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 243 | 0.040 |
Why?
|
| Health Status | 1 | 2019 | 360 | 0.040 |
Why?
|
| Louisiana | 1 | 2016 | 17 | 0.040 |
Why?
|
| Demography | 1 | 2016 | 177 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1313 | 0.030 |
Why?
|
| Propensity Score | 1 | 2016 | 136 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 2017 | 177 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 816 | 0.030 |
Why?
|
| Animals | 1 | 2015 | 26590 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 2894 | 0.030 |
Why?
|
| Monitoring, Ambulatory | 1 | 2015 | 32 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 1824 | 0.030 |
Why?
|
| Observer Variation | 1 | 2015 | 603 | 0.030 |
Why?
|
| Ischemic Attack, Transient | 1 | 2015 | 181 | 0.030 |
Why?
|
| Health Personnel | 1 | 2015 | 202 | 0.030 |
Why?
|
| Enteral Nutrition | 1 | 2013 | 102 | 0.030 |
Why?
|
| Gastrostomy | 1 | 2013 | 69 | 0.030 |
Why?
|
| Hypertension | 1 | 2019 | 1142 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 2706 | 0.020 |
Why?
|